Electrophysiology Market Forecasts to 2028 – Global Analysis By Product (EP laboratory devices, EP diagnostic catheters, EP ablation catheters, Access devices and Other Types), Indication (Atrioventricular Nodal Reentry Tachycardia (AVNRT), Atrial fibril

Electrophysiology Market Forecasts to 2028 – Global Analysis By Product (EP laboratory devices, EP diagnostic catheters, EP ablation catheters, Access devices and Other Types), Indication (Atrioventricular Nodal Reentry Tachycardia (AVNRT), Atrial fibrillation (AF) and Other Indications), End User and By Geography

According to Stratistics MRC, the Global Electrophysiology Market is accounted for $7.57 billion in 2022 and is expected to reach $14.47 billion by 2028 growing at a CAGR of 11.4% during the forecast period. Electrophysiology (EP) is a scientific discipline that investigates electrical activity in the body. It is also known as invasive cardiac electrophysiology, and it is a series of tests that analyse the electrical activity of the heart. It is used to diagnose and treat cardiac rhythm disorders or arrhythmias by measuring the electrical system or activity of the heart. During the test, catheters and wire electrodes are utilised to assess electrical activity in blood vessels that lead to the heart.

According to the World Obesity Atlas 2022, 1 in 3 men (34.41%) and nearly two-fifths of women (39.72%) are expected to have a BMI of 30kg/m2 by 2030 in the Americas area.

Market Dynamics:

Driver:

The increasing prevalence of heart arrhythmias, ophthalmic issues, and epilepsy

The introduction of innovative technologies such as cryoablation, laser ablation, ultrasonic ablation, and enhanced mapping technologies is expected to increase the global electrophysiology market over the forecast period. The market is also being fueled by the increased prevalence of heart failure (HF) and cardiac arrest cases among millennials as a result of lifestyle choices such as smoking and excessive alcohol consumption. Furthermore, smaller EP monitoring systems have raised demand for these devices in the worldwide electrophysiology industry, particularly during the COVID-19 period. As a result, the cardiac rhythm and failure divisions are paying careful attention to remote monitoring and the programming capabilities of implanted electrophysiology (EP) devices.

Restraint:

High cost

The cost of constructing the EP laboratory has risen significantly over the years due to variables such as healthcare provider consolidation, growing expenses due to the usage of complicated medical treatments, changing government restrictions, and limited resources. This is limiting the penetration of these goods, despite the fact that knowledge of arrhythmia and the usefulness of electrophysiological products to treat arrhythmia is increasing in various nations.

Opportunity:

Rising number of emerging markets

Emerging markets are expected to offer significant growth opportunities for players in this market, owing to their increasing patient population, rising adoption of cardiac mapping systems, growing awareness of CVDs, rising disposable incomes, improving healthcare infrastructure, and comparatively lenient guidelines when compared to developed countries. During the last decade, emerging countries have seen a steady increase in the number of surgical procedures, driven by a larger target patient population, an increase in CVD-related fatalities, and increased medical tourism.

Threat:

Refurbished devices

The rising demand for refurbished products presents a significant challenge for market participants, particularly small producers. To enhance their market position and build a significant user base for their electrophysiological goods, market players must either drop their pricing or develop better or more advanced technologies that can answer the market's unmet needs.

Covid-19 Impact

The unexpected breakout of the COVID-19 pandemic has had a mixed influence on the worldwide medical equipment business. Some categories suffered an overall negative impact as a result of the global drop in the number of patient visits to hospitals. Patients with pre-existing cardiac disease who are exposed to COVID-19, on the other hand, are more likely to experience a heart attack or develop congestive heart failure. The decline has led to limited demand for electrophysiology devices, hampering the growth of the market. Additionally, key market players operating in the market witnessed decline in the revenues generated from these devices in the first half of 2020.

The EP laboratory devices segment is expected to be the largest during the forecast period

The EP laboratory devices segment is estimated to have a lucrative growth, Due to the increasing public-private funding for the development of novel electrophysiology recording systems, the rising number of RF ablation procedures, the cost-effectiveness of RF ablation procedures in comparison to other ablation techniques, and the expanding availability of these products in major markets. EP laboratory devices are further subdivided into EP X-Ray systems, 3D mapping systems, EP recording systems, EP remote steering systems, and others.

The atrial fibrillation (AF) segment is expected to have the highest CAGR during the forecast period

The atrial fibrillation (AF) segment is anticipated to witness the highest CAGR growth during the forecast period. Atrial fibrillation (AF), commonly known as AFib, is one of the most prevalent kinds of arrhythmia, resulting in irregular and fast heart rhythms. It happens when rapid electric signals drive the upper chamber of the heart to contract quickly, preventing the atria from pumping blood into the ventricles regularly, resulting in blood clots. Atrial fibrillation patients are more likely to get serious heart issues such as strokes and heart failure. AFib contributes to nearly one in every six strokes.

Region with highest share:

North America is projected to hold the largest market share during the forecast period because of the rising prevalence of heart failure (HF), cardiac arrest, and cardiac arrhythmia as a result of unhealthy lifestyles and increased smoking and alcohol intake. The presence of proper reimbursement policies in the region is also one of the primary factors likely to drive market expansion. While the majority of the population in America is obese, they are predisposed to cardiovascular disease, which is likely to boost market growth.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to increasing activities by key market players in countries in the region. The fast growth of healthcare infrastructure and rising disposable income in developing countries such as India and China are expected to drive up demand for electrophysiology devices. Furthermore, it is projected that top industry companies in the region will boost their investment due to the region's fast rising healthcare infrastructure and growing healthcare spending.

Key players in the market

Some of the key players profiled in the Electrophysiology Market include Japan LifeLine Co., Ltd., MicroPort Scientific Corporation, Osypka Medical, Abbott, GE Healthcare, Siemens Healthcare GmbH, APN Health, LLC, Koninklijke Philips N.V., Medtronic, Stereotaxis, Inc., Johnson & Johnson, Japan LifeLine Co., Ltd., Boston Scientific Corporation and Acutus Medical, Inc.

Key Developments:

In January 2022, Abbott has received the U.S. Food and Drug Administration for its EnSite X EP System with EnSite Omnipolar Technology (OT). It is a new cardiac mapping platform available in the US and across Europe that is designed to help physicians better treat abnormal heart rhythms. The system creates highly detailed three-dimensional maps of the heart to help physicians identify and then treat areas of the heart where abnormal rhythms originate.

In October 2021, Boston Scientific Corporation has entered into a definitive agreement to acquire Baylis Medical Company Inc. for $1.75 billion. The acquisition will help Boston Scientific.

In December 2020, Acutus has announced the launch of their AcQBlate Force Sensing Ablation System in Europe after getting the CE Mark. The AcQBlate Force Sensing Ablation System, designed with commercially available gold-tipped, irrigated, force-sensing radiofrequency ablation catheter, it is used for electrophysiology mapping and RF ablation.

Products Covered:
• EP laboratory devices
• EP diagnostic catheters
• EP ablation catheters
• Access devices
• Other Products

Indications Covered:
• Atrioventricular Nodal Reentry Tachycardia (AVNRT)
• Atrial fibrillation (AF)
• Wolff-Parkinson-White Syndrome (WPW)
• Atrial flutter
• Other Indications

End Users Covered:
• Ambulatory surgery centers
• Hospitals & cardiac centers
• Other End Users

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements